|
Getting your Trinity Audio player ready...
|
By Omboki Monayo
Nairobi, Kenya: As Kenyans celebrated the 62nd Jamhuri Day with pomp and colour in Nairobi on December 12, 2025, a significant announcement was made 12,150 kilometres away in Washington, DC.
The U.S. Food and Drug Administration (FDA) approved Nuzolvence® (zoliflodacin). For the first time in decades, the world has a new antibiotic developed exclusively to treat gonorrhoea—a sexually transmitted infection that has become a chilling emblem of the global antimicrobial resistance (AMR) crisis.
This milestone is more than a scientific breakthrough. It represents a radical shift in how lifesaving medicines can be developed and delivered through not‑for‑profit partnerships that prioritise public health over profit.
Gonorrhoea is one of the most common sexually transmitted infections worldwide, with an estimated 82 million new cases annually. Behind these numbers lies a troubling reality: Neisseria gonorrhoeae has steadily outpaced medical science, developing resistance to nearly every antibiotic used against it.
For years, ceftriaxone stood as the last reliable line of defence. But resistance to this drug has surged six‑fold in some regions, raising the frightening spectre of gonorrhoea becoming the first disease to slip back into the category of “untreatable.”
The approval of zoliflodacin, a top-tier oral antibiotic, offers a desperately needed reprieve. Administered as a single dose, it treats uncomplicated urogenital gonorrhoea in adults and adolescents aged 12 and above. It works by targeting bacterial enzymes essential for reproduction, setting it apart from existing therapies and making it effective against multidrug‑resistant strains.
A Different Kind of Partnership
What makes Nuzolvence® remarkable is not only its clinical promise but also the way it was developed. The Global Antibiotic Research & Development Partnership (GARDP), a Geneva‑based non‑profit, spearheaded the pivotal Phase 3 trial in collaboration with Innoviva Specialty Therapeutics.
“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea,” said Dr. Manica Balasegaram, GARDP’s Executive Director. “Zoliflodacin shows that a different public‑private partnership approach to antibiotic development is possible—one that prioritises global health needs, strengthens access where the burden is highest, and protects the effectiveness of new drugs for the long‑term.”
The trial itself was unprecedented in scope. Conducted across 930 participants in 16 sites spanning Belgium, the Netherlands, South Africa, Thailand, and the United States, it deliberately included underrepresented populations—women, adolescents, and people living with HIV. This diversity ensures the drug’s effectiveness in real‑world conditions, not just idealised laboratory settings.
Kenya’s HIV and STI Burden
The urgency of this breakthrough is particularly evident in Kenya. Current data show an HIV prevalence of 3.03%, with about 1.3 million people living with HIV. In 2025 alone, Kenya recorded 20,105 new infections, disproportionately affecting women (13,236) compared to men (6,869). Despite commendable progress—87% of people living with HIV are on antiretroviral therapy—the country still reported 21,009 AIDS-related deaths this year.
Alongside HIV, Kenya faces a rising tide of sexually transmitted infections, including gonorrhoea, syphilis, chlamydia, and HPV. These infections compromise reproductive health and increase vulnerability to HIV transmission. Gonorrhoea, in particular, has become harder to treat as resistance to ceftriaxone spreads. Without new options, Kenya risks facing untreatable strains that could worsen its HIV epidemic and overwhelm already stretched health systems.
Why Nuzolvence® Matters for Kenya
The arrival of Nuzolvence® offers a crucial solution. As a single-dose oral treatment, it simplifies care, reduces the need for injections, and improves adherence—a critical pillar in resource-limited settings. Its demonstrated effectiveness against multidrug-resistant Neisseria gonorrhoeae restores hope where treatment options are dwindling.
Equally important, by limiting its use exclusively to gonorrhoea, GARDP and its partners aim to preserve the drug’s effectiveness for longer. This stewardship approach is vital for Kenya, where antibiotic misuse has historically accelerated resistance.
Treating gonorrhoea effectively also strengthens HIV prevention. STIs cause mucosal inflammation, which increases susceptibility to HIV infection. By reducing gonorrhoea prevalence, Nuzolvence® indirectly helps curb new HIV transmissions—a double win for Kenya’s public health agenda.
Clinicians in high‑burden countries have welcomed the development with relief. In Thailand, Dr. Rossaphorn Kittiyaowamarn of the Bangrak STI Medical Center described the approval as “a game changer”.
